| Literature DB >> 31242603 |
Abstract
Macrocyclic diterpenoids produced by plants of the Euphorbiaceae family are of considerable interest due to their high structural diversity; and their therapeutically relevant biological properties. Over the last decade many studies have reported the ability of macrocyclic diterpenoids to inhibit in cellulo the cytopathic effect induced by the chikungunya virus. This review; which covers the years 2011 to 2019; lists all macrocyclic diterpenoids that have been evaluated for their ability to inhibit viral replication. The structure-activity relationships and the probable involvement of protein kinase C in their mechanism of action are also detailed.Entities:
Keywords: Euphorbiaceae; PKC; chikungunya; daphnane; flexibilane; ingenane; jatrophane; phorbol; pre-myrsinane; tigliane
Year: 2019 PMID: 31242603 PMCID: PMC6631467 DOI: 10.3390/molecules24122336
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of tiglianes 1–51 and ingenanes 52–54.
Anti-chikungunya virus (CHIKV) activities of tiglianes 1–51 and ingenanes 52–54.
| Compound | CHIKV EC50 | SI | R1 | R2 | R3 | |
|---|---|---|---|---|---|---|
|
| ||||||
|
| Phorbol | >343 | >1 | HO- | HO- | HO- |
|
| Phorbol-12-acetate | >245 | 0.8 | AcO- | HO- | HO- |
|
| Phorbol-12-decanoate | 4.9 ± 1.7 | 1.5 | DecO- | HO- | HO- |
|
| Phorbol-13-acetate | >174 | n.d. | HO- | AcO- | HO- |
|
| Phorbol-13-butyrate | 20 ± 10 | 12.3 | HO- | BuO- | HO- |
|
| Phorbol-13-decanoate | 2.2 ± 0.1 | 9.7 | HO- | DecO- | HO- |
|
| Phorbol-13-tetradecanoate | 0.99 ± 0.03 | 9.0 | HO- | TetradecO- | HO- |
|
| Phorbol-12,13-diacetate | 9.4 ± 1.0 | 4.2 | AcO- | AcO- | HO- |
|
| Phorbol-12,13-dibutyrate | 1.8 ± 0.2 | 2.1 | BuO- | BuO- | HO- |
|
| Phorbol-12,13-dihexanoate | 3.2 ± 0.2 | 1.8 | HexO- | HexO- | HO- |
|
| Phorbol-12,13-didecanoate | 6.0 ± 0.9 nM | 686 | DecO- | DecO- | HO- |
|
| 4α-Phorbol-12,13-didecanoate | 1.5 ± 0.1 | 2.2 | DecO- | DecO- | HO- |
|
| Phorbol-13,20-diacetate | 24.6 ± 7.1 | 1.7 | HO- | AcO- | AcO- |
|
| Phorbol-12,13,20-triacetate | 32.6 ± 4.0 | 2.2 | AcO- | AcO- | AcO- |
|
| 12- | 2.9 ± 0.3 nM | 1965 | TetradecO- | AcO- | HO- |
|
| 12- | 2.8 ± 0.5 | 1.9 | TetradecO- | AcO- | HO- |
|
| 12- | 1.1 ± 0.3 | 3.3 | TiglO- | DecO- | HO- |
|
| 12- | 15 ± 4 | 1.1 | MA- | AcO- | HO- |
|
| 12,13- | 0.6 ± 0.1 | 3.7 | NonO- | NonO- | HVA- |
|
| 12- | 1.7 ± 0.3 | 14.2 | PhAcO- | AcO- | HVA- |
|
| Trigowiin A | >100 | >2.3 | DodecO- | AcO- | - |
|
| 12- | 3.3 ± 0.3 | 41 | AcO- | mBuO- | HO- |
|
| 12- | 2.4 ± 0.3 | 2.0 | DecO- | AcO- | HO- |
|
| 12- | 4.0 ± 0.8 | 1.9 | - | - | - |
|
| 20-Oxo-phorbol-12,13-dibutyrate | 13.1 ± 0.5 | 2.7 | BuO- | BuO- | O= |
|
| 20-Oxo-TPA | 0.7 ± 0.1 | 5.9 | TetradecO- | AcO- | O= |
|
| 12β- | <0.7 | >77 | iBuO- | HO- | |
|
| 12β- | <0.7 | >12 | mBuO- | HO- | |
|
| 12β- | <0.8 | >58 | DecadiO- | iBuO- | HO- |
|
| 12β- | 4.5 ± 0.6 | 6 | DecadiO- | iBuO- | - |
|
| ||||||
|
| 12β- | 77 | 1.4 | AcO- | mBuO- | - |
|
| 12β- | 1.4 ± 0.2 | 5.1 | NontriO- | BuO- | - |
|
| 4β-Deoxyphorbol-12-tiglate-13-isobutyrate | 1.0 ± 0.4 | 25 | TiglO- | iBuO- | - |
|
| 4α-Deoxyphorbol-12-tiglate-13-isobutyrate | 17.0 ± 1.0 | 7 | TiglO- | iBuO- | - |
|
| 4β-Deoxyphorbol-12-acetate-13-isobutyrate | 0.44 ± 0.03 | 390 | AcO- | iBuO- | - |
|
| 12β- | 0.9 ± 0.1 | 6 | DecadiO- | iBuO- | - |
|
| 12β- | 0.6 ± 0.6 | 41 | DecatriO- | iBuO- | - |
|
| 12β- | 0.4 ± 0.02 | 34 | OctaDiO- | iBuO- | - |
|
| 12β- | 12.6 ± 46.2 | 4 | 7-DecatriO- | iBuO- | - |
|
| ||||||
|
| 4α,20-Dideoxyphorbol-12-tiglate-13-isobutyrate | 51.1 ± 4.1 | 3 | - | - | - |
|
| ||||||
|
| 12-Deoxyphorbol-13-acetate (prostratin) | 2.7 ± 1.2 | 22.8 | H- | AcO- | HO- |
|
| 13- | 0.7 ± 0.1 | 5.0 | H- | BuO- | AcO- |
|
| 13- | 50.8 ± 2.1 | 1.9 | H- | PhAcO- | AcO- |
|
| 12-Deoxyphorbol-13(2″-methyl)butyrate | 1.2 ± 0.2 | >240 | H- | mBuO- | HO- |
|
| 12-Deoxyphorbol-13-[8′-oxo- hexadeca-2E,4E,6E-trienoate] | 2.2 ± 1.5 | 5.9 | H- | OxoHDTO- | HO- |
|
| 12-Deoxyphorbol-13-hexadecanoate | 0.02 ± 0.001 | 1500 | H- | HexadecO- | HO- |
|
| 12-Deoxy-5β-hydroxy-phorbol-13-hexadecanoate | 0.13 ± 0.03 | 98 | H- | HexadecO- | HO- |
|
| 12-Deoxy-6,7-epoxy-5β-hydroxy-phorbol-13-hexadecanoate | 0.09 ± 0.05 | 54 | - | - | - |
|
| 12-Deoxy-5β,6β,7α-trihydroxy-phorbol-13-hexadecanoate | 2.14 ± 0.3 | 26 | - | - | - |
|
| ||||||
|
| 4α-12-Dideoxyphorbol-13(2,3-dimethyl)butyrate-20-acetate | >11 | n.d | - | dBuO- | OAc- |
|
| 4β-12-Dideoxyphorbol-13(2,3-dimethyl)butyrate-20-acetate | 4.0 ± 0.3 | 10.6 | - | dBuO- | OAc- |
|
| ||||||
|
| Ingenol | 30.1 ± 19.2 | 4.8 | HO- | HO- | - |
|
| Ingenol-3-mebutate | 22.9 ± 5.2 | 2.3 | MbO- | HO- | - |
|
| Ingenol-3,20-dibenzoate | 1.2 ± 0.1 | 6.4 | BzO- | BzO- | - |
| Chloroquine | 10 ± 5 | 8.9 | - | - | - |
EC50s are given in μM, unless otherwise stated. Values are the median ± median absolute deviation calculated from at least three independent assays. SI, selectivity index, calculated as CC50 Vero/EC50 CHIKV. n.d. = not determined (EC50 50% effective concentration or concentration which is calculated to inhibit virus induced cell death by 50%, and CC50 50% antimetabolic concentration or concentration which is calculated to inhibit the overall cell metabolism by 50%). Anti-CHIKV results obtained with the methodology from Bourjot et al. [21].
Figure 2Structure–activity relationships of tiglianes.
Figure 3Structures of daphanes 55–66.
Anti-CHIKV activities of daphnanes 55–66.
| Compound | CHIKV EC50 | SI | |
|---|---|---|---|
|
| |||
|
| Resiniferatoxin | 1.8 ± 0.2 | 2.3 |
|
| Trigocherrierin A | 0.6 ± 0.1 | 71.7 |
|
| Trigocherrin A | 1.5 ± 0.6 | 23 |
|
| Trigocherrin B | 2.6 ± 0.7 | 36 |
|
| Trigocherrin F | 3.0 ± 1.2 | 7.7 |
|
| Trigocherriolide A | 1.9 ± 0.6 | 2.4 |
|
| Trigocherriolide B | 2.5 ± 0.3 | 2.1 |
|
| Trigocherriolide C | 3.9 ± 1.0 | 2.7 |
|
| Trigocherriolide E | 0.7 ± 0.1 | 9.4 |
|
| Neoguillauminin A | 17.7 ± 0.8 | 2 |
|
| Codiapeltine A | 10.0 ± 2.3 | 5 |
|
| Codiapeltine B | 4.4 ± 0.5 | 11 |
| Chloroquine | 10 ± 5 | 8.9 | |
EC50s are given in μM; values are the median ± standard deviation calculated from at least three independent assays. SI, selectivity index, calculated as CC50 Vero/EC50 CHIKV. n.d. = not determined. Anti-CHIKV results obtained with the methodology from Bourjot et al. [21].
Figure 4Structures of jatrophanes 67–92.
Anti-CHIKV activities of jatrophanes 67–92.
| Compound Name | CHIKV EC50 | SI | R1 | R2 | R3 | R4 | R5 | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
|
| 3,5,7,8,15-Pentaacetoxy-2-hydroxy-9,14-dioxojatropha-6(17),11E-diene | >164 | n.d. | AcO- | H | - | - | - |
|
| 3,5,7,15-Tetraacetoxy-2-hydroxy-8-isobutyryloxy-9,14-dioxojatropha-6(17),11E-diene | >196 | n.d. | iBuO- | H | - | - | - |
|
| 3,5,7,15-Tetraacetoxy-2-hydroxy-8-tigloyloxy-9,14-dioxojatropha-6(17),11E-diene | 0.76 ± 0.14 | 208 | TiglO- | H | - | - | - |
|
| 3,5,7,15-Tetraacetoxy-8-benzoyloxy-2-hydroxy-9,14-dioxojatropha-6(17),11E-diene | 4.3 ± 0.2 | 29 | BzO- | H | - | - | - |
|
| esulatin B | 60 ± 14 | >2.6 | AcO- | AcO- | - | - | - |
|
| 2,3,5,7,15- Pentaacetoxy-8-tigloyloxy-9,14-dioxojatropha-6(17),-11E-diene | 17.4 ± 0.7 | 8.3 | TiglO- | AcO- | - | - | - |
|
| 2,3,5,8,15- Pentaacetoxy-7-benzoyloxy-9,14-dioxojatropha-6(17),11E-diene | 17.1 | >2.9 | BzO- | AcO- | - | - | - |
|
| ||||||||
|
| 5,7,14- Triacetoxy-3-benzoyloxy-8,15-dihydroxy-9-oxojat-opha-6(17),11E-diene | 19.5 ± 3.6 | 7.8 | AcO- | H | - | - | - |
|
| 5,7-Diacetoxy-3-benzoyloxy-14,15-dihydroxy-8-isobutyryloxy-9-oxojatropha-6(17),11E-diene | 21.0 ± 3.4 | 2.8 | iBuO- | H | - | - | - |
|
| 5,7-Diacetoxy-3-benzoyloxy-14,15-dihydroxy-8-(2-methylbutyryloxy)-9-oxojatropha-6(17),11E-diene | 111 ± 14 | >1.7 | mBuO- | H | - | - | - |
|
| 5,7,14-Tri- acetoxy-3-benzoyloxy-15-hydroxy-9-oxojatropha-6(17),11E-diene | 80 ± 6 | 1.9 | H | AcO- | - | - | - |
|
| ||||||||
|
| Euphodendroidin E | >29.2 | n.d | H | AcO- | iBuO- | BzO- | AcO- |
|
| Euphodendroidin F | 57.3 | 1.9 | HO- | AcO- | iBuO- | BzO- | AcO- |
|
| Euphodendroidin J | >144.4 | n.d. | HO- | BzO- | HO- | BzO- | AcO- |
|
| Euphodendroidin A | >28.6 | n.d. | AcO- | H | iBuO- | BzO- | AcO- |
|
| Euphodendroidin K | >124.4 | <1.0 | AcO- | iBuO- | iBuO- | BzO- | AcO- |
|
| Euphodendroidin L | >44.9 | n.d. | AcO- | AcO- | iBuO- | BzO- | AcO- |
|
| Euphodendroidin M | >42.8 | n.d. | AcO- | AcO- | iBuO- | iBuO- | AcO- |
|
| Euphodendroidin B | 133.6 | 0.5 | AcO- | H | mBuO- | BzO- | AcO- |
|
| Euphodendroidin N | >42.5 | 1.1 | AcO- | H | BzO- | BzO- | AcO- |
|
| Euphodendroidin O | 27.4 | 1.3 | AcO- | H | BzO- | BzO- | H |
|
| 2,3,5,7,8,9,15-Heptahydroxyjatropha-6(17),11-diene-14-one 2,5,8, 9-tetraacetate-3-(benzoyloxyacetate)-7-(2-methyl-propionate) | 5.5 ± 1.7 | 3.2 | AcO- | BzOAcO- | AcO- | iBuO- | AcO- |
|
| ||||||||
|
| 13α-Terracinolide G | >132.6 | n.d. | AcO- | AcO- | HO- | H | - |
|
| 13α-Terracinolide B | >125.6 | n.d. | AcO- | AcO- | HO- | AcO- | - |
|
| Terracinolide C | 15.0 ± 3.8 | 2.4 | AcO- | iBuO- | H | H | - |
|
| Terracinolide J | >135.4 | n.d. | H | AcO- | H | AcO- | - |
| Chloroquine | 10 ± 5 | 8.9 | - | - | - | - | - | |
EC50s are given in μM, unless otherwise stated. Values are the median ± median absolute deviation calculated from at least three independent assays. SI, selectivity index, calculated as CC50 Vero/EC50 CHIKV. n.d. = not determined. Anti-CHIKV results obtained with the methodology from Bourjot et al. [21].
Figure 5Structures of premysinanes 93–99 and myrsinane 100.
Anti-CHIKV activities of premysinanes 93–99 and myrsinane 100.
| Compound | CHIKV EC50 | SI | R1 | R2 | R3 | R4 | R5 | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
|
| 3β,7β,13β,17- | 78 | 2.2 | AcO- | BzO- | AcO- | AcO- | H |
|
| 3β,7β,15β,17- | >152 | n.d. | AcO- | BzO- | AcO- | H | AcO- |
|
| 3β,7β,13β,17- | >50 | <5 | AcO- | mBuO- | AcO- | AcO- | H |
|
| 7β,13β,17- | 107 | 2.2 | PrO- | mBuO- | AcO- | AcO- | H |
|
| 7β,17- | >107 | <2.4 | PrO- | BzO- | AcO- | NicO- | H |
|
| 13β,17- | 11 ± 1.4 | 5.8 | PrO- | BzO- | H | H | AcO- |
|
| Premyrsinol-3-propanoate-5-benzoate-7,13,17-triacetate | >144 | n.d. | PrO- | BzO- | AcO- | AcO- | H |
|
| ||||||||
|
| 5α,7β- | 84 | 1.9 | - | - | - | - | - |
| Chloroquine | 10 ± 5 | 8.9 | - | - | - | - | - |
EC50s are given in μM, unless otherwise stated. Values are the median ± median absolute deviation calculated from at least three independent assays. SI, selectivity index, calculated as CC50 Vero/EC50 CHIKV. n.d. = not determined. Anti-CHIKV results obtained with the methodology from Bourjot et al. [21].
Figure 6Structures of flexibilanes 101–110.
Anti-CHIKV activities of flexibilanes 101–110.
| Compound | CHIKV EC50 | SI | |
|---|---|---|---|
|
| |||
|
| tonantzitlolone A | >215 | n.d. |
|
| tonantzitlolone B | 12 ± 3 | 10.2 |
|
| tonantzitlolone C | 24 ± 1 | >9 |
|
| tonantzitlolone D | >222 | n.d. |
|
| tonantzitlolone E | >107 | n.d. |
|
| tonantzitlolone F | 19 ± 2 | 3 |
|
| tonantzitlolone G | 168 | >1.3 |
|
| tonantzitlolone H | >191 | n.d. |
|
| tonantzitlolone I | >208 | n.d. |
|
| tonantzitloic acid | >201 | n.d. |
| chloroquine | 10 ± 5 | 8.9 | |
EC50s are given in μM; values are the median ± standard deviation calculated from at least three independent assays. SI, selectivity index, calculated as CC50 Vero/EC50 CHIKV. n.d. = not determined. Anti-CHIKV results obtained with the methodology from Bourjot et al. [21].